A Phase 3 interventional study of LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2020-08-07.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 13th largest by enrollment, is one of 2 that started in 2017, is one of 10 in phase 3, and was the 17th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →
lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2017.
This study's enrollment of 57 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 66 across the 20 interventional studies. Of the 20 that completed or were terminated, 15 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 1 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 72nd largest by enrollment of the 116 interventional ones that give a count, is one of 7 that started in 2017, is one of 62 in phase 3, and was the 64th registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing lumacaftor in Cystic Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for F508del.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects entering the Treatment Cohort must meet the following criteria:
Subjects entering the Observational Cohort must meet 1 of the following criteria:
Exclusion Criteria (Treatment Cohort Only):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
Drug: LUM/IVA
Drug pages: Lumacaftor · Ivacaftor
Participants received LUM/IVA every q12h.
Also known as: VX-809/VX-770, lumacaftor/ivacaftor
Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Day 1 up to Week 98
Absolute Change in Sweat Chloride
Sweat samples were collected using an approved collection device.
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in BMI-for-age Z-score
BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Weight
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Weight-for-age Z-score
Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change From Baseline in Stature (Height)
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Stature-for-age Z-score
Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
Time frame: From Parent Study 115B Baseline at Week 96
Time-to-first Pulmonary Exacerbation
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.
Time frame: From Parent Study 115B Baseline through Week 96
Number of Pulmonary Exacerbations (PEx)
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.
Time frame: From Parent Study 115B Baseline through Week 96
Number of Cystic Fibrosis (CF) Related Hospitalizations
Time frame: From Parent Study 115B Baseline through Week 96
Absolute Change in Fecal Elastase-1 (FE-1) Levels
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels
Time frame: From Parent Study 115B Baseline at Week 96
Number of Participants With Microbiology Culture Status (Positive or Negative)
Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.
Time frame: Week 96
Absolute Change in Lung Clearance Index (LCI) 2.5
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: From Parent Study 115B Baseline at Week 96
Absolute Change in Lung Clearance Index (LCI) 5.0
LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
Time frame: From Parent Study 115B Baseline at Week 96
This study was planned to have 2 cohorts: Treatment Cohort and Observational Cohort. Only the Treatment Cohort is presented in results as there were no participants enrolled in the Observational Cohort.
| Milestone | LUM/IVA |
|---|---|
| Started | 57 |
| Study 115b fas | 60 |
| Study 116 fas | 57 |
| Study 116 lci substudy set | 31 |
| Completed | 47 |
| Not completed | 10 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal of consent (not due to ae) | 1 |
| Withdrew: Physician decision | 2 |
| Withdrew: Commercial drug is available | 5 |
| participants | LUM/IVA |
|---|---|
| Participants with AEs | 56 |
| Participants with SAEs | 15 |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | LUM/IVA |
|---|---|
| Absolute Change in Sweat Chloride | -29.6 ± 12.7 |
BMI was defined as weight in kilogram (kg) divided by height in square meter (m\^2).
| kg/m^2 | LUM/IVA |
|---|---|
| Absolute Change in Body Mass Index (BMI) | 0.30 ± 1.21 |
BMI was defined as weight in kilograms divided by height in m\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA |
|---|---|
| Absolute Change in BMI-for-age Z-score | 0.27 ± 0.73 |
| kg | LUM/IVA |
|---|---|
| Absolute Change in Weight | 6.0 ± 2.0 |
Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA |
|---|---|
| Absolute Change in Weight-for-age Z-score | 0.23 ± 0.56 |
| centimeter | LUM/IVA |
|---|---|
| Absolute Change From Baseline in Stature (Height) | 16.1 ± 2.3 |
Z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.
| z-score | LUM/IVA |
|---|---|
| Absolute Change in Stature-for-age Z-score | 0.07 ± 0.39 |
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.
| days | LUM/IVA |
|---|---|
| Time-to-first Pulmonary Exacerbation | 600.0 (98.0 to NA) |
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol-defined criteria.
| pulmonary exacerbation events | LUM/IVA |
|---|---|
| Number of Pulmonary Exacerbations (PEx) | 82 |
| hospitalizations | LUM/IVA |
|---|---|
| Number of Cystic Fibrosis (CF) Related Hospitalizations | 28 |
| microgram per gram (mcg/g) | LUM/IVA |
|---|---|
| Absolute Change in Fecal Elastase-1 (FE-1) Levels | 132.6 ± 174.2 |
| nanogram per milliliter (ng/mL) | LUM/IVA |
|---|---|
| Absolute Change in Immunoreactive Trypsinogen (IRT) Serum Levels | -108.5 ± 306.6 |
Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.
| participants | LUM/IVA |
|---|---|
| Burkholderia (Positive) | 0 |
| Burkholderia (Negative) | 46 |
| MRSA (Positive) | 4 |
| MRSA (Negative) | 42 |
| MSSA (Positive) | 15 |
| MSSA (Negative) | 31 |
| P. Aeruginosa Mucoid (Positive) | 0 |
| P. Aeruginosa Mucoid (Negative) | 46 |
| P. Aeruginosa Non-Mucoid (Positive) | 1 |
| P. Aeruginosa Non-Mucoid (Negative) | 45 |
| P. Aeruginosa Small Colony Variant (Positive) | 0 |
| P. Aeruginosa Small Colony Variant (Negative) | 46 |
| Stenotrophomonas Maltophilia (Positive) | 2 |
| Stenotrophomonas Maltophilia (Negative) | 44 |
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| lung clearance index | LUM/IVA |
|---|---|
| Absolute Change in Lung Clearance Index (LCI) 2.5 | -0.20 ± 1.55 |
LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.
| lung clearance index | LUM/IVA |
|---|---|
| Absolute Change in Lung Clearance Index (LCI) 5.0 | 0.11 ± 0.65 |
Collected over Day 1 up to Week 98. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM/IVA | 0/57 (0%) | 15/57 (26.3%) | 55/57 (96.5%) |
| Event | LUM/IVA |
|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 6/57 |
| PneumoniaInfections and infestations | 2/57 |
| ConstipationGastrointestinal disorders | 1/57 |
| HaematemesisGastrointestinal disorders | 1/57 |
| PancreatitisGastrointestinal disorders | 1/57 |
| AppendicitisInfections and infestations | 1/57 |
| Chronic sinusitisInfections and infestations | 1/57 |
| Gastritis viralInfections and infestations | 1/57 |
| Gastroenteritis adenovirusInfections and infestations | 1/57 |
| Gastroenteritis viralInfections and infestations | 1/57 |
| Event | LUM/IVA |
|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 47/57 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 25/57 |
| PyrexiaGeneral disorders | 23/57 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 18/57 |
| VomitingGastrointestinal disorders | 17/57 |
| Upper respiratory tract infectionInfections and infestations | 13/57 |
| Ear infectionInfections and infestations | 12/57 |
| SinusitisInfections and infestations | 12/57 |
| Staphylococcus test positiveInvestigations | 12/57 |
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 10/57 |
| Age, Continuous(months) | LUM/IVA |
|---|---|
| Mean | 43.2 ± 12.17 |
| Sex: Female, Male(Participants) | LUM/IVA |
|---|---|
| Female | 28 |
| Male | 29 |
| Ethnicity (NIH/OMB)(Participants) | LUM/IVA |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 54 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | LUM/IVA |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 56 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2017 to primary completion in Jul 2019, 26 months.
Results were first posted in Aug 2020, 1 year after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 26 months is close to that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lumacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →